<!DOCTYPE html>
<html>
<head>
	<meta charset="UTF-8">
	<link rel="stylesheet" type="text/css" href="stylesheets/style.css">
	<script type="text/javascript" src="scripts/script.js"></script>
	<title>final</title>
</head>
<body>
	<div class="container">
		<header>
			<nav>
				<div class="tab active_t">
					<p>Graphics</p>
				</div>
				<div class="tab">
					<p>Calculator</p>
				</div>
				<div class="tab">
					<p>Competitors</p>
				</div>
			</nav>	
		</header>
		<section>
			<article class="page active_p">
				<div class="graphics_header">
					<h1>Xarelto<sup>&reg;</sup>: An Effective Treatment Option<br>in Your VTE Patients with Canser<sup>a,8</sup></h1>
				</div>
				<div class="graphics_content">
					<div class="sidebar">
						<p>%PATIENTS<sup>b</sup></p>	
					</div>
					<div class="diagram">
						<div class="y_axis">
							<ul>
								<li>8 -</li>
								<li>7 -</li>
								<li>6 -</li>
								<li>5 -</li>
								<li>4 -</li>
								<li>3 -</li>
								<li>2 -</li>
								<li>1 -</li>
								<li>0</li>
							</ul>
						</div>
						<div class="diagram_header">
							<h2>HR 0.69;<br>95% CL 0.36-1.33</h2>
						</div>
						<div class="left_column">
							<p>7.1</p>
							<p>n=20/281</p>
							<p>ENOXAPARIN/<br>VKA</p>
						</div>
						<div class="right_column">
							<p>5.1</p>
							<p>n=16/316</p>
							<p>XALERTO</p>
						</div>
						<div class="x_axis">
							<p>Cancer</p>
						</div>
						
					</div>
				</div>
				<div class="graphics_footer">
					<p><sup>a</sup>Xalerto is contraindicated in lesions or conditions, if they are considered to be a significant for major<br> bleeding, which may include the presence of malignant neoplasms at hirisk of bleeding.</p>
					<p><sup>b</sup>Outcome:symptomatic, recurrent VTE.</p>
				</div>
			</article>
			<article class="page">
				<div class="calculator_header">
					<h1>Xarelto<sup>&reg;</sup> Estimator of Resources Saved</h1>
				</div>
				<div class="calculator_content">
					<div class="left_calculator"></div>
					<div class="right_calculator"></div>
				</div>
				<div class="calculator_footer">
					<p>Numbers provided are based on general epidemiological research and on clinical trial experience from the Phase III programme with Xalerto. Healthcare practice<br>may be different in your country(both before and after introduction Xalerto), and thus the estimation may not reflect your country's perspective.</p>
					<p>Actual costs are not included.</p>
				</div>
			</article>
			<article class="page">
				<div class="competitors_header">
					<h1>Xarelto<sup>&reg;</sup> DVT Patients Reported Higher Satisfaction<sup>a,16</sup></h1>
				</div>
				<div class="competitors_content">
					
				</div>
				<div class="competitors_footer">
					<p><sup>a</sup>Patients participating in EINSTEIN DVT trial had confirmed acute symptomatic DVT without symptomatic PE and completed two measures of treatment satisfaction;<br> ATS (Anti Clot Treatment Scale) and TSQM (Treatment Satisfaction Questionnaire for Medication) in follow up visits.<sup>5, 16</sup></p>
					<p><sup>b</sup>Score values given for burdens and benefits measured by ACTS; effectiveness, side effects, convenience and global satisfaction measured by TSQM scale.<sup>16</sup></p>
				</div>
			</article>
		</section>
		<script type="text/javascript" src="scripts/script.js"></script>
	</div>
</body>
</html>
